entertainment -WSS

entertainment

author：explore 2025-09-06 04:13:23 - browse：31

Medical illustration of Streptococcus pneumoniae bacteria — A medical illustration of drug-resistant, Streptococcus pneumoniae bacteria. Antibiotic Resistance Coordination and Strategy Unit/CDC

Micronoma, a San Diego-based biotech startup, was founded on the idea that signatures from microbes that colonize tumors could lead to a blood test to detect cancer. The hypothesis was based on a high-profile Nature paper, published in 2020, that suggested these microbes are consistently found in tumors, and that they create such specific signatures they could be used to identify cancer types with nearly 100% accuracy.

But late Monday night, a team of researchers published a manuscript on the preprint site bioRxiv.com showing what they believe to be two “fatal errors” in the Nature paper’s analyses, invalidating not only the paper’s findings but possibly the scientific foundation for Micronoma, which has raised an estimated $17.5 million in funding from investors including SymBiosis Capital Management and the Seerave Foundation.

One allegation is that the Nature paper’s authors didn’t adequately filter out human DNA from their database of tumor samples, leading them to incorrectly classify millions of human sequences as bacterial. The other is that a separate error led the team’s algorithm to find false associations between specific microbial signatures and cancer types.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： FDA approves Eli Lilly ulcerative colitis treatment Omvoh

WSS

Readout Newsletter: XBI biotech index, Akero Therapeutics

Hospitals need to get ahead of regulations on climate change

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

Ozempic cut risk of death in diabetes patients with chronic kidney disease

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Physician subsidies by hospitals soar in wake of No Surprises Act

focus

entertainment

focus

Guidelines to prevent youth baseball injuries need more muscle

Biden's order seeks to regulate AI risk without stifling innovation

Drug repurposing or repositioning? The language matters

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The FDA weighs the risks of candy

Walensky prepares to leave CDC — and Congress — behind

Maker of FluMist seeks to allow at

Sports medicine is finally prioritizing gender equality

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

hotspot

The pink breast cancer awareness ribbon needs a redesign

Guardant Health colon cancer test endorsed by FDA advisory panel

The world needs the new pandemic treaty

Readout Newsletter: XBI biotech index, Akero Therapeutics

Readout Newsletter: What happened with Sarepta's Duchenne data

Readout Newsletter: XBI biotech index, Akero Therapeutics

focus

entertainment

focus

focus